Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Katherine R. Pelz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2169-0613; OpenAlex author ID A5008438303; NIH RePORTER profile ID 78766092. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
50
Papers, trials and grants by year

2019: 4 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 5 papers · 2026: 2 papers, 1 grant

Papers 13

  1. Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. First author DOI 10.1002/jcsm.70253↗
  2. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
  3. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Co-author DOI 10.1101/2025.07.14.664767↗
  4. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  5. MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia. Co-author DOI 10.1158/2767-9764.crc-25-0414↗
  6. Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Surviva… Co-author DOI 10.1200/jco-25-01631↗
  7. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cac… Co-author DOI 10.1200/jco.23.01965↗
  8. Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis. Co-author DOI 10.1002/jcsm.13466↗
  9. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Co-author DOI 10.1038/s41467-021-22361-3↗
  10. MyD88 signalling is critical in the development of pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12377↗
  11. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-12657-w↗
  12. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-13151-z↗
  13. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-18-0717↗

Grants 1

  1. HuR’s role in pancreatic cancer metastasis F30CA306284↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Robert Brody · 4 shared papers, 2025–2026 · strength 0.92
  2. Rosalie C. Sears · 5 shared papers, 2019–2026 · strength 0.89
  3. Aaron J. Grossberg · 4 shared papers, 2021–2026 · strength 0.83
  4. Teresa A Zimmers · 3 shared papers, 2025 · strength 0.66
  5. Kevin Hawthorne · 3 shared papers, 2025–2026 · strength 0.55
  6. Lisa M. Coussens · 4 shared papers, 2019–2026 · strength 0.55
  7. Grace A. McCarthy · 2 shared papers, 2026 · strength 0.50
  8. Paige C. Arneson‐Wissink · 2 shared papers, 2024–2026 · strength 0.50
  9. Robert L Eil · 2 shared papers, 2024–2026 · strength 0.44
  10. Terry K. Morgan · 4 shared papers, 2019–2025 · strength 0.43
  11. Patrick Joseph Worth · 2 shared papers, 2025 · strength 0.43
  12. Brittany L. Allen-Petersen · 3 shared papers, 2019–2025 · strength 0.41
  13. Susann Theile · 2 shared papers, 2025 · strength 0.41
  14. Denis C. Guttridge D · 2 shared papers, 2025 · strength 0.41
  15. Dorte Lisbet Nielsen · 2 shared papers, 2025 · strength 0.41
  16. Julia Sidenius Johansen · 2 shared papers, 2025 · strength 0.41
  17. Olav Faisal Dajani · 2 shared papers, 2025 · strength 0.41
  18. Inna Markovna Chen · 2 shared papers, 2025 · strength 0.41
  19. Michael C. Ostrowski · 2 shared papers, 2025 · strength 0.41
  20. Katie E. Blise · 2 shared papers, 2025–2026 · strength 0.39
  21. Vidhi M. Shah · 2 shared papers, 2025–2026 · strength 0.38
  22. Kevin G. Burfeind · 4 shared papers, 2019–2021 · strength 0.38
  23. Brennan G. Olson · 4 shared papers, 2019–2021 · strength 0.38
  24. Katherine A. Michaelis · 4 shared papers, 2019–2021 · strength 0.38
  25. Xinxia Zhu · 4 shared papers, 2019–2021 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.